The Trump administration is using a Fifth Circuit decision over the No Surprises Act to ask the Supreme Court to consider whether lower courts have authority to universally vacate agency rules under ...

HHS is again demanding responses from several leading medical organizations on their stances regarding transgender care for children, saying that if the groups, several of which are embroiled in legal ...

The American Medical Association (AMA) wants to work with CMS to develop payment codes for breakthrough devices moving through a new expedited coverage pathway, according to comments submitted to the ...

Health policy stakeholders and former FDA officials are backing a group of bipartisan drug development reforms they say could boost domestic clinical research and expand patient access to treatments, ...

The U.S. Customs and Border Protections has punted to mid-January a rule that could prevent Americans from obtaining some pharmaceuticals from certified foreign pharmacies, drawing cautious praise ...

Ranking House Energy & Commerce Committee Democrat Frank Pallone (NJ) introduced a bill Thursday (Oct. 8) to replace the No Surprises Act’s arbitration process with a payment benchmark, drawing ...

The lobby for Medicare Advantage plans launched a six-figure ad campaign highlighting how MA beneficiaries’ views on health care affordability and choice will influence their votes in November.

A national patient advocacy group focused on lowering prescription drug prices is urging U.S. Customs and Border Protection to let FDA exercise enforcement discretion so patients can maintain access ...

A new group of hospitals is rallying for the United States District Court for the District of Maine to once again block the government from implementing a pilot program that will replace upfront ...

With Congress out of session and a short holiday week, there are fewer events for health care stakeholders to attend this week, but FDA will hold several events focused on generic drug development, ...

FDA on Wednesday (Oct. 14) launched a Rare Disease Framework Initiative that it says will reform the development of rare disease treatments by considering each disease’s specific patient population ...

Following the release of a chiding government report finding slow product reviews and issues tracking performance at FDA’s Center for Tobacco, the newly appointed director of the center is urging ...